title: [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
abstract: High-dose (75 mg/m2) cisplatin is baseline chemotherapy in lung cancer. To prevent nephrotoxicity, patients generally receive saline infusion on the day of chemotherapy prior to and following cisplatin (total of 3.5-4.0 liters during 3-4 hours). Despite these measures nephrotoxicity has remained frequent, especially among patients also suffering from cardiovascular disease or diabetes mellitus. Since 2005 several international recommendations have been formed about prevention of cisplatin nephrotoxicity. According to these recommendations: 1) renal function should not be evaluated by serum creatinine concentration; 2) evaluation of renal function should be based on calculated creatinine clearance (e.g. by the Cockcroft-Gault equation); 3) patients to be treated by high-dose cisplatin should be euvolemic and should have saline diuresis (urine NaCl concentration ~1%) of at least 100 ml/hour prior to, during and several days following the administration of cisplatin. Keeping these recommendations ensures prolonged cisplatin treatability of lung cancer patients. Moreover, decreased renal function will not limit the full dose administration of several other cytotoxic agents. Losonczy G, Máthé C, Müller V, Szondy K, Moldvay J. Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer.
authors.affiliation: Semmelweis Egyetem Pulmonológiai Klinika 1125 Budapest Diós árok út 1/c. losonczy@pulm.sote.hu
authors.forename: György
authors.initials: G
authors.lastname: Losonczy
authors.forename: Csaba
authors.initials: C
authors.lastname: Máthé
authors.forename: Veronika
authors.initials: V
authors.lastname: Müller
authors.forename: Klára
authors.initials: K
authors.lastname: Szondy
authors.forename: Judit
authors.initials: J
authors.lastname: Moldvay
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000453:epidemiology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D015897:Comorbidity; D003404:Creatinine / Q000097:blood; D048909:Diabetes Complications / Q000453:epidemiology; D005060:Europe; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D015994:Incidence; D007391:International Cooperation; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D007677:Kidney Function Tests; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism / Q000517:prevention & control*; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D000970:Antineoplastic Agents; D003404:Creatinine; D002945:Cisplatin